9 Results

People

  1. Hudis
    Hudis
  2. Modi
    Modi
  3. Patil
    Patil
  4. Baselga
    Baselga
  5. Norton
    Norton
  6. Seidman
    Seidman
  7. Aniapam Boafo
    Aniapam Boafo
  8. Beal
    Beal
  9. Chen
    Chen
  10. D'Andrea-Carlino
    D'Andrea-Carlino

Groups

  1. Department of Medicine (7)
  2. Solid Tumor Oncology Division (7)
  3. Breast Medicine Service (6)
  4. Biostatistics Service (3)
  5. Epidemiology and Biostatistics (3)
  6. Survivorship Research (3)
  7. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (2)
  8. Cardiology (2)
  9. Division of Subspecialty Medicine (2)
  10. Body Imaging Service (1)
  1. "her2-positive"
Formats
  1. Journal Article (7)
  2. Book Section (1)
  3. Editorial (1)
Groups
  1. Department of Medicine (7)
  2. Solid Tumor Oncology Division (7)
  3. Breast Medicine Service (6)
  4. Biostatistics Service (3)
  5. Epidemiology and Biostatistics (3)
  6. Survivorship Research (3)

More Groups

People
  1. Clifford Hudis (3)
  2. Shanu Modi (3)
  3. Sujata Patil (3)
  4. Andrew Seidman (2)
  5. Jose Baselga (2)
  6. Larry Norton (2)

More People

Years
  1. 2021 (1)
  2. 2018 (2)
  3. 2017 (1)
  4. 2015 (2)
  5. 2012 (2)
  6. 2006 (1)
Publications
  1. Annals of Oncology (1)
  2. Breast Cancer Research and Treatment (1)
  3. Cancer (1)
  4. Clinical Breast Cancer (1)
  5. Future Oncology (1)
  6. Gastric Cancer: Principles and Practice (1)

More Publications

Publishers
  1. Oxford University Press (2)
  2. Springer (2)
  3. Elsevier Inc. (1)
  4. Future Medicine (1)
  5. Impact Journals (1)
  6. Nature Publishing Group (1)

More Publishers

Results (9)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study
    Editorial

    Modi, S.
    Future Oncology (2021)

    Fulltext@MSK | Save
  • Characteristics and prognostic factors for patients with HER2-overexpressing breast cancer and brain metastases in the era of HER2-targeted therapy: An argument for earlier detection
    Journal Article

    Morikawa, A.; Wang, R.; Patil, S.; Diab, A.; Yang, J.; Hudis, C. A.; McArthur, H. L.; Beal, K.; Seidman, A. D.
    Clinical Breast Cancer (2018)

    Fulltext@MSK | Save
  • Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases
    Journal Article

    De Mattos-Arruda, L.; Ng, C. K. Y.; Piscuoglio, S.; Gonzalez-Cao, M.; Lim, R. S.; De Filippo, M. R.; Fusco, N.; Schultheis, A. M.; Ortiz, C.; Viteri, S.; more...
    Oncotarget (2018)

    Fulltext@MSK | Save
  • Pathologic complete response with neoadjuvant doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab and pertuzumab in patients with HER2-positive early stage breast cancer: A single center experience
    Journal Article

    Singh, J. C.; Mamtani, A.; Barrio, A.; Morrow, M.; Sugarman, S.; Jones, L. W.; Yu, A. F.; Argolo, D.; Smyth, L. M.; Modi, S.; more...
    The Oncologist (2017)

    Fulltext@MSK | Save
  • Role of HER2 in gastric cancers
    Book Section

    Won, E.; Janjigian, Y. Y.
    In Strong, V. E. (Eds.) Gastric Cancer: Principles and Practice (2015)

    Fulltext@MSK | Save
  • Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status
    Journal Article

    Nuciforo, P. G.; Aura, C.; Holmes, E.; Prudkin, L.; Jimenez, J.; Martinez, P.; Ameels, H.; de la Pena, L.; Ellis, C.; Eidtmann, H.; more...
    Annals of Oncology (2015)

    Fulltext@MSK | Save
  • A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer
    Journal Article

    Beeram, M.; Krop, I. E.; Burris, H. A.; Girish, S. R.; Yu, W.; Lu, M. W.; Holden, S. N.; Modi, S.
    Cancer (2012)

    Fulltext@MSK | Save
  • Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer
    Journal Article

    Gajria, D.; Gonzalez, J.; Feigin, K.; Patil, S.; Chen, C.; Theodoulou, M.; Drullinsky, P.; D'Andrea, G.; Lake, D.; Norton, L.; more...
    Breast Cancer Research and Treatment (2012)

    Fulltext@MSK | Save
  • Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer? Commentary
    Journal Article

    Seidman, A. D.
    Nature Clinical Practice Oncology (2006)

    Fulltext@MSK | Save